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What is Gaucher disease? 
Gaucher disease is caused by mutations in the Gba1 
gene encoding an acid β-glucocerebrosidase (GBA1), the 
lysosomal hydrolase which breaks down glucosylceramide 
(GlcCer). In Gaucher type 1 disease the accumulation 
of this simple glycolipid is mainly restricted to tissue 
phagocyte lysosomes resulting ultimately in hepatomegaly, 
splenomegaly and osteopenia. Lower residual GBA1 levels 
leads to neuronal storage, in types 2 and 3 neurological 
symptoms are characterised by acute (death at age 2) or sub-
acute onset, respectively. The links between cellular changes 
and clinical manifestations are largely unknown but are the 
key to the development and monitoring of new therapies.
The newcomer to Gaucher disease is likely attracted to 
the apparent simplicity of an autosomal recessive disorder 
which promises to unravel the critical GlcCer function 
in normal cells (GlcCer is widespread, it’s even present in 
some bacteria—also, mouse and fly GlcCer knockouts die at 
embryo stage). However, closer acquaintance reveals not a 
classic Mendelian disorder—sometimes even monozygotic 
twins have different symptoms—and studies at the cellular 
level have so far failed to reveal clear GlcCer functions. 
Now a team led by Ellen Sidransky at the NIH has taken 
what appears to be a big step forward by producing two 
in vitro models of Gaucher cells (1).
How has Gaucher disease been investigated?
Research has been hampered by the inaccessibility of 
Gaucher macrophages and the lack of in vitro models. The 
simplest approach has been to induce a Gaucher phenotype 
by treating cells with the GBA1 inhibitor, conditurol-
β-epoxide. Whilst this method has the virtues of being 
cheap and experimentally easy, off-target effects are not 
controlled for. For instance, conduritol-β-epoxide also 
inhibits a related enzyme, GBA2 (2). Inhibition of this non-
lysosomal enzyme has been reported to rescue mutations in 
lysosomal GBA1 (3). GlcCer is unusual amongst glycolipids 
with intracellular trafficking connecting both lysosomal 
and non-lysosomal pools on both sides of the bilayer 
membrane (4). GlcCer transporters have been identified 
(5-7) but the relationships between different pools of 
GlcCer are still unclear.
A second approach has been to use fibroblasts from 
Gaucher patients. Although the macrophage-centric view of 
Gaucher disease has recently been questioned (8), Gaucher 
skin fibroblasts are not important in Gaucher disease and 
don’t store GlcCer.
What has now been achieved?
The researchers selected 20 Gaucher patients representing 
a total of 4 genotypes. Monocytes were extracted from these 
patients and differentiated into macrophages by the use 
of M-CSF: the resulting cells being termed hMacs. This 
method, whilst relatively quick and cheap, does not lead to a 
sustainable cell line. This was addressed by taking Gaucher 
fibroblasts from 4 patients and transformed them into 
induced pluripotent stem cells (iPSCs), then to monocytes 
and finally macrophages, referred to as iMacs. Whilst 
expensive and difficult, the use of stem cell technology 
means that this method does generate a sustainable cell line. 
Control cells of both types were produced from blood and 
fibroblasts donated by healthy volunteers.
Researchers examined the two cell types produced, hand-in-
hand with an evaluation of previously disclosed (9) prototype 
drug NCGC00188758. This belongs to the class of molecules 
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known as molecular chaperones: binding to the enzyme (in this 
case GBA1) correcting the misfolding. This results in repaired 
transport to the lysosome and enhanced GBA1 function.
Gratifyingly the phenotypes of hMacs and iMacs 
resembled genuine Gaucher cells. Compared with control 
macrophages, both cell types showed reduced impaired 
GBA1 activity and impaired transport of mutant GBA1 to 
lysosomes, indicated by colocalisation with the lysosomal 
marker LAMP2. Crucially, and in marked contrast to 
Gaucher fibroblasts, both cell types accumulated GlcCer 
and glucosylsphingosine. Cellular defects were rescued 
by treatment with NCGC00188758. Indeed, this small 
molecule drug was slightly more effective at restoring 
GBA1 activity than imiglucerase, an enzyme commonly 
used in enzyme replacement therapy.
Chemotaxis was found to be reduced versus controls, 
an observation previously reported for some, though not 
all, Gaucher patients (10). Whilst the Gaucher model cells 
were found to phagocytose IgG-opsonised erythrocytes and 
bacteria normally, dysfunction was found in the production 
of reactive oxygen species (ROS). Thus iMacs and hMacs 
had lower concentration of ROS in the resting state, and 
no further generation of ROS upon phagocytosis. These 
findings mirror previous reports on impaired superoxide 
generation in Gaucher cells (10,11). Importantly both 
chemotaxis and ROS production were restored on 
treatment with NCGC00188758.
Gaucher links with Parkinson’s disease
The potential medical significance of Gaucher disease 
does not end with the condition itself. Most attention has 
been focussed on the unexpected finding that having even 
one mutant copy of the Gba1 gene is a significant risk 
factor for Parkinson’s disease (12). This has prompted 
research interest into the possible links between Gaucher 
disease and Parkinson’s disease. The most fundamental 
observation is that poorly functional GBA1 is associated 
with the accumulation of α-synuclein (α-syn) (13) leading 
to neuronal death. This protein can fold and aggregate 
in many different ways and a possible mechanism for 
its accumulation is the stabilisation of oligomers by 
GlcCer (13). In turn, α-syn can inhibit GBA1 (14), an 
observation that may well account for the reduced levels 
of GBA1 activity seen in post mortem brains of sporadic 
Parkinson’s disease patients (15). Furthermore, α-syn 
can interfere with vesicular traffic of GBA1 from the ER 
to the Golgi (13). Thus, by means of a bi-directional 
loop, even a slight loss of GBA1 function can become 
magnified. A qualification to the above discussion 
arises from the observation that post-mortem brains 
of patients suffering from all types of Gaucher disease 
had monomeric, but not oligomeric α-syn (16). Further 
work is needed to unravel the exact mechanism by which 
mutant Gba1 gives rise to α-syn aggregates. Further 
explorations of the consequences of this accumulation 
of cytosolic, insoluble α-syn are also required. It has 
been shown, for example, that in normal neurones α-syn 
is localised at the synaptic membrane [where it plays a 
role in regulating synaptic vesicles (17)] and that this 
localisation is mediated by lipid rafts (18). How these 
changes relate to increased raft-forming GlcCer has yet 
to be addressed.
Future research using Gaucher cell models
Recent research has revealed interdependence of 
phagosome pH and ROS generation (19) hence decreased 
generation of ROS might be linked to increased pH of 
Gaucher lysosomes (20). Increased pH may also explain 
reduced lysosomal proteolysis (13), co-storage of cholesterol 
and disrupted membrane trafficking in Gaucher cells (21). 
Alternatively, glucosylsphingosine (GlcSph) may mediate 
decreased ROS (22). Whilst interest has generally focussed 
on GlcSph as a biomarker for Gaucher disease, it’s still 
an open question whether enough GlcSph escapes the 
lysosome to inhibit Protein kinase C [IC50 =85 µM (23)]. 
However, PKC has also been implicated in the phagocytosis 
of opsonised bacteria (24).
Several workers have reported increased levels of 
inflammatory markers, including M-CSF, in the serum of 
patients with Gaucher disease. These observations raise 
the possibility that this could be the cause of the reported 
proliferation of osteoclasts associated with Gaucher disease 
(25,26) and the consequent occurrence of bone symptoms 
in some patients.
In conclusion it appears that the researchers have 
produced both a realistic model of Gaucher cells and a 
promising prototype drug. Although much work is required 
before NCGC00188758 can be considered as a usable drug 
in patients, there is a particular lack of treatment options for 
the neurodegenerative forms of Gaucher disease (12,27).
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